Acrobiosystems Co.,Ltd. (SHE:301080)
76.02
-7.60 (-9.09%)
Nov 16, 2026, 4:00 PM EST
Acrobiosystems Revenue
Acrobiosystems had revenue of 301.05M CNY in the quarter ending September 30, 2026, with 33.43% growth. This brings the company's total for the last twelve months to 1.03B, up 29.11% year-over-year. In the year 2025, Acrobiosystems had annual revenue of 838.12M with 29.94% growth. That makes Acrobiosystems the 19,436th largest company in the world by revenue and 3,557th in China.
Revenue (ttm)
1.03B
Revenue Growth
+29.11%
P/S Ratio
12.43
Revenue / Employee
1.11M
Employees
926
Market Cap
12.75B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Acrobiosystems breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 838.12M | 193.10M | 29.94% |
| Dec 31, 2024 | 645.02M | 101.37M | 18.65% |
| Dec 31, 2023 | 543.65M | 69.22M | 14.59% |
| Jan 1, 2023 | 474.43M | 89.44M | 23.23% |
| Jan 1, 2022 | 384.99M | 138.67M | 56.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.34B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.60B |
| Nanjing Vazyme Biotech | 1.56B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |
| GemPharmatech | 941.80M |